SecBot SecBot
6-K ·Filed Sep 10, 2026

KMDA

KAMADA LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago SEC0001213900-26-098574
Actionable Insight • Neutral

Monitor the conference presentation and any subsequent press releases for potential business updates or strategic announcements. No immediate trading action warranted based on this filing alone.

DirectionNeutral
Confidencehigh
Horizonimmediate

Drugs in focus

KMDA drug pipeline →

CYTOGAM

● Neutral Named in this 6-K
Impact
Phase
Approved
Time to market
Already FDA-approved and commercially marketed
Next catalyst
None dated

What to watchCYTOGAM contributes ~12-13% of Kamada's total revenue (~$22.5M in 2024) and is growing 31% YoY, but is not a binary catalyst for the stock. Watch Q2 2026 earnings (~Aug 12, 2026) for CYTOGAM sales trajectory and any updates on the SHIELD study. The stock's primary drivers are Glassia (alpha-1 antitrypsin) and KEDRAB (rabies IG), which represent larger revenue streams.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$7.99
T+0 close · Sep 10, 2026 · via day close
Latest settled
−2.69%
T+20 · $7.78 · next T+60 in 17d
Vs SPY
−4.82%
α at T+20
Latest observation
+3.63%
T+45 · FF3 residual α
  1. T+0 · Sep 10 $7.99entry
  2. T+1 · 2mo ago −0.88%α −1.73% · $7.92
  3. T+5 · 2mo ago +8.51%α +9.01% · $8.67
  4. T+20 · 6w ago −2.69%α −4.82% · $7.78
  5. T+47 · todayOpen
  6. T+60 · in 17d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kamada announced that CEO Amir London will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. This is a routine investor relations event with no new material financial or operational data disclosed. The filing provides no financial figures, guidance, or business updates beyond the conference participation.

Key Facts

  • CEO Amir London to present at H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026 at 2:30 PM ET.
  • One-on-one investor meetings will be available throughout the conference.
  • No financial results, guidance, or material business developments were disclosed in this filing.

Financial Impact

No financial impact, routine conference participation announcement only.

Risk Factors

  • No material risks disclosed in this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 10 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (KMDA), Batch item 10001213900-26-098574
Document: ea030509101ex99-1.htm0001213900-26-098574
Document: 0001213900-26-098574-index-headers.html0001213900-26-098574
Document: 0001213900-26-098574-index.html0001213900-26-098574
Document: 0001213900-26-098574.txt0001213900-26-098574
6-K Filing (KMDA), Batch item 60001213900-26-098574
Document: ea030509101ex99-1.htm0001213900-26-098574
Document: 0001213900-26-098574-index-headers.html0001213900-26-098574
Document: 0001213900-26-098574-index.html0001213900-26-098574
Document: 0001213900-26-098574.txt0001213900-26-098574

Track record

25 reports on KMDA

Performance horizon

8 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +16.13% at T+20 after the Aug 12, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 9, 20267d ago 6-K Bullish 6/10 No price data
  2. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $7.71 to $8.11 Now $8.11 +5.19% ▲ +5.19% +6.88% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $7.36 to $7.71 Now $8.11 +10.19% ▲ +4.76% +4.68% vs SPY
  4. Oct 6, 20265w ago 6-K Neutral 4/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  5. Oct 6, 20265w ago Press Release Bullish 6/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  6. Oct 5, 20266w ago 6-K Neutral 2/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  7. Sep 17, 20268w ago 6-K Bullish 6/10 Entry $8.67 to $8.83 Now $8.11 −6.46% ▲ +1.85% +1.24% vs SPY
  8. Sep 16, 20268w ago EFFECT Neutral 3/10 Entry $8.19 to $8.77 Now $8.11 −0.98% ▲ +7.08% +4.52% vs SPY
  9. Sep 10, 20269w ago 6-K Neutral 2/10 Viewing Entry $7.99 to $8.67 Now $8.11 +1.50% ▲ +8.51% +9.01% vs SPY
  10. Sep 3, 202610w ago Press Release Neutral 2/10 Entry $8.54 to $8.31 Now $8.11 −5.04% ▼ −2.69% −1.48% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 9h 25m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 10, 2026